PUBLISHER: The Business Research Company | PRODUCT CODE: 1751172
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751172
Vitreoretinal disorder encompasses a group of eye conditions that impact the retina and the vitreous humor, both of which are essential for preserving the eye's shape and ensuring visual clarity. These conditions can lead to progressive vision impairment and often require advanced diagnostic tools and specialized medical or surgical treatments for proper management.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of vitreoretinal disorders include retinal tears, retinal detachment, diabetic retinopathy, macular degeneration, macular holes, and others. A retinal tear is a small break or hole in the retina, the light-sensitive layer at the back of the eye. Diagnosis involves various techniques such as digital fluorescein angiography, optical coherence tomography, Heidelberg retinal tomography, indocyanine green angiography, among others. Treatment options include surgery, medication, and additional approaches. These treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and serve a range of end users including hospitals, home care settings, specialty clinics, and others.
The vitreoretinal disorder market research report is one of a series of new reports from The Business Research Company that provides vitreoretinal disorder market statistics, including vitreoretinal disorder industry global market size, regional shares, competitors with a vitreoretinal disorder market share, detailed vitreoretinal disorder market segments, market trends and opportunities, and any further data you may need to thrive in the vitreoretinal disorder industry. This vitreoretinal disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The vitreoretinal disorder market size has grown strongly in recent years. It will grow from$4.30 billion in 2024 to $4.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising prevalence of diabetic retinopathy, an aging population, increased awareness of retinal diseases, the expansion of healthcare infrastructure, and the early adoption of anti-vascular endothelial growth factor (VEGF) therapy.
The vitreoretinal disorder market size is expected to see strong growth in the next few years. It will grow to$6.30 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The projected growth in the forecast period can be attributed to the rising prevalence of age-related macular degeneration, an increasing incidence of diabetic retinopathy, growing investment in regenerative stem cell therapies, higher healthcare spending on eye diseases, greater awareness of early retinal disease detection, and supportive government initiatives. Key trends expected during this period include AI-powered retinal disease detection, robotic-assisted vitreoretinal surgeries, nanotechnology-based drug delivery systems, smart contact lenses for real-time eye monitoring, ultra-high-resolution adaptive optics imaging, and biodegradable intravitreal implants.
The increasing prevalence of diabetic retinopathy is expected to drive the growth of the vitreoretinal disorder market in the years ahead. Diabetic retinopathy is an eye disease resulting from damage to the retinal blood vessels caused by prolonged high blood sugar levels in individuals with diabetes. This condition is becoming more common due to the growing number of diabetes cases, largely fueled by sedentary lifestyles and inadequate blood sugar control, which lead to retinal vascular damage. Vitreoretinal disorder treatment is essential for managing diabetic retinopathy by addressing issues such as vitreous hemorrhage and tractional retinal detachment, thus helping to preserve vision and minimize further retinal harm. For example, in October 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that during 2022-23, 1.8% of screened First Nations individuals received treatment for diabetic retinopathy, with an age-standardized treatment rate of 1.3%, compared to 1.5% for non-Indigenous Australians. Therefore, the increasing incidence of diabetic retinopathy is contributing to the expansion of the vitreoretinal disorder market.
Leading companies in the vitreoretinal disorder market are developing advanced therapies, such as methotrexate-based treatments, to target primary vitreoretinal lymphoma-a rare and aggressive form of retinal cancer. This approach involves the intravitreal administration of methotrexate, a chemotherapy drug, to suppress cancerous cells in the retina and vitreous, providing a focused and effective treatment. For instance, in December 2022, Aldeyra Therapeutics Inc., a biotechnology company based in the U.S., announced a successful pre-New Drug Application (pre-NDA) meeting with the FDA regarding ADX-2191. This product is a novel, preservative-free methotrexate formulation designed to treat primary vitreoretinal lymphoma (PVRL), offering a promising solution for this rare condition.
In July 2024, Merck & Co. Inc., a U.S.-based pharmaceutical giant, acquired Eyebiotech Limited (EyeBio) for $3 billion. This strategic move aims to expand Merck's portfolio in the field of ophthalmology by adding Restoret (EYE103), a promising therapy for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Eyebiotech Limited, headquartered in the UK, is a clinical-stage biotech firm focused on developing treatments for retinal disorders, including vitreoretinal diseases.
Major players in the vitreoretinal disorder market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Baxter International, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Topcon Corporation, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., and Clearside Biomedical.
North America was the largest region in the vitreoretinal disorder market in 2024. The regions covered in vitreoretinal disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vitreoretinal disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vitreoretinal disorder market includes revenues earned by entities by providing services such as diagnostic services, intravitreal injection therapies, imaging services, teleophthalmology consultations, postoperative care, and retinal rehabilitation services. The vitreoretinal disorder market also includes sales of fundus cameras, injections, and steroid implants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vitreoretinal Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vitreoretinal disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for vitreoretinal disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vitreoretinal disorder market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.